| Document |
Document Title |
|
WO/2003/072537A2 |
Compounds of formula (I), or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the ...
|
|
WO/2003/072539A1 |
The present invention relates to novel compounds of formula (I),to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of ...
|
|
WO/2003/070692A1 |
A compound represented by the following formula (1): (1) (wherein R1 represents C1-12 alkyl, phenyl, 1-naphthyl, etc.; R2 represents C2-12 alkyl; (R3)b represent zero to four substituents, e.g., halogeno; R4 represents lower alkyl; R5 re...
|
|
WO/2003/066579A2 |
The present invention is directed to certain bicyclic hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical c...
|
|
WO/2003/066581A1 |
The present invention is directed to compounds of the structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof: Formula I (a) R1, R2 and R6 are each independently selected from the group consisting of ...
|
|
WO/2003/066889A2 |
This invention is directed to a continuous method for measuring the activity of an enzyme that catalyzes the addition of an acetyl group to a residue capable of being acetylated or an enzyme that catalyzes the removal of an acetyl group ...
|
|
WO/2003/062192A1 |
Cycloalkyl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such cycloalkyl ketoamide derivatives as well as methods of using the same in the ...
|
|
WO/2003/060523A1 |
The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NA...
|
|
WO/2003/057169A2 |
The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infect...
|
|
WO/2003/055848A2 |
This invention relates to urea derivatives of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof: (I) wherein Y is R1- R6 and X have the same meanings given in the description, which is useful as an active ingredie...
|
|
WO/2003/051841A2 |
Carbamates and related compounds of formula R1 R2NCO-Y or R1 R2NCS-Y wherein R1 and R2 are hydrogen, alkyl, aryl, heteroaryl or may together form a piperidine, piperazine, morpholine or other heterocyclic ring, are inhibitors of hormone ...
|
|
WO/2003/051842A2 |
Carbamates and related compounds of formula R1R2NCO-Y or R1R2NCS-Y wherein R1 and R2 may form a ring, are inhibitors of hormone sensitive lipase and are useful for the treatment of any disorder where it is desirable to modulate the plasm...
|
|
WO/2003/050066A1 |
This invention is directed to functionalized higher diamondoids having at least one functional group. These derivatives have a higher diamondoid nucleus and up to six independently selected functional groups. The functionalized higher di...
|
|
WO/2003/048115A1 |
Compounds of formula (I) are antibacterial agents: wherein: Z is −N(OH)CH(=O) or −C(=O)NH(OH)&semi R1 represents hydrogen, methyl or trifluoromethyl or, except when Z is a radical of formula −N(OH)CH(=O), a hydroxy, halo or amino g...
|
|
WO/2003/048108A2 |
Novel acyl urea, thiourea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine−mediated inflammatory response in cultured cells, in ameliorating bone destruction, in an animal mode...
|
|
WO/2003/047568A1 |
The present invention discloses compounds of the formula I which, are novel antagonists for melanin−concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceut...
|
|
WO/2003/037865A1 |
The present invention relates to compounds of formula (I): (I) their pharmacologically acceptable salts, or solvates and hydrates, and their prodrugs, respectively, and to pharmaceutical compositions containing the same as active ingredi...
|
|
WO/2003/034989A2 |
Acylated $g(a)-hydroxyarylbutanamines and related sulfonamides, ureas and carbamates that inhibit aspartyl protease are disclosed, as are methods of treating diseases, particularly HIV, using these compounds. The compounds have the formu...
|
|
WO/2003/030889A1 |
The present invention relates to compounds of the general formula (I), their preparation and use as pharmaceutical compositions asintegrin antagonists, especially as $g(a)¿4?$g(b) and/or $g(a)¿4?$g(b)¿7 ?and/or $g(a)¿9?$g(b)¿1? inte...
|
|
WO/2003/029198A1 |
The invention relates to the use of compounds having general formula X-(A)¿n?-Y, wherein: n varies between 6 and 20; X denotes a hydrogen atom, an R¿a?CO, R¿a?OCO, R¿a?NHCO or R¿a?SO¿2? group, R¿a? being an alkyl, alkenyl, alkynyl...
|
|
WO/2003/024448A2 |
The invention relates to the inhibition of histone deacetylase. The invention provides compounds e.g. (1) and methods for inhibiting deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell p...
|
|
WO/2003/024920A1 |
The current invention provide novel compounds, methods of treating preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological di...
|
|
WO/2003/024921A1 |
The current invention provides compounds of the general formula (I), methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, can...
|
|
WO/2003/024955A2 |
The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein A, B, D, E, G, J, n, and R1 are as described generally and in classes and subclasses herein, and additionally provi...
|
|
WO/2003/024439A1 |
The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of...
|
|
WO/2003/022799A1 |
The present invention relates to 1,2-diaminocyclopentane derivatives of Formula (I), wherein R¿1? - R¿4? are as defined in the specification. The compounds are useful as CCR-3 receptor antagonists, and therefore, may be used for the tr...
|
|
WO/2003/020688A1 |
Compounds of formula (I) or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the c...
|
|
WO/2003/018535A2 |
The invention relates to a novel class of aminobenzophenones derivatives, to pharmaceutical preparations comprising said compounds, to dosage units of such preparations, to methods of treating patients comprising administering said compo...
|
|
WO/2003/018536A1 |
The invention provides 1,2-substituted cyclic compounds useful for treatment of diseases or disorders arising from abnormal or inappropriate cell proliferation, such as tumour growth, tumour metastasis and associated angiogenesis, as wel...
|
|
WO/2003/014064A1 |
Naphthylurea and naphthylacetamide derivatives of formula (I) which have vanilloid receptor 1 (VR1) antagonistic activity are disclosed, formula (I) wherein Y represents formula (II) and formula (III) and the variables Q, X, R6, R7, R8, ...
|
|
WO/2003/014296A2 |
Compounds containing a specific saturated or unsaturated branched chain terminal group; a polar leading group; and a long-chain aliphatic, non-cyclic, saturated or unsaturated, substituted or unsubstituted, hydrocarbon group linking them...
|
|
WO/2003/011223A2 |
The present invention is directed to novel compounds that function as immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases, to novel adjuvant formulations which include at least one...
|
|
WO/2003/010135A1 |
Phenylpropionic acid derivatives represented by the general formula (1): (1) (2−1) [wherein A is a group represented by the general formula (2−1) or the like&semi R10 to R13 are each hydrogen or the like&semi Arm is a benzene ring or...
|
|
WO/2003/006422A1 |
Compounds having general formula (I): wherein: -R represents a hydrogen atom, a C¿1?-C¿8? alkyl or haloalkyl group, a C¿2?-C¿8? alkoxyalkyl or haloalkoxyalkyl group, a C¿2?-C¿8? alkenyl or haloalkenyl group, a C¿2?-C¿8? alkinyl o...
|
|
WO/2003/005965A2 |
The present invention relates to compounds which can be used as inhibitors of mitochondrial ceramidase, in particular human mitochondrial ceramidase. The invention also relates to methods of designing and making the compounds, as well as...
|
|
WO/2003/004458A1 |
The present invention relates to 2-(benzoylamino)benzoic acid derivatives of the formula (I), wherein the variants Ar, X and R are described in the specification. The said compounds modulate the activity of peroxisome proliferator-activa...
|
|
WO/2003/004460A2 |
The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment ...
|
|
WO2002070467B1 |
The invention relates to new diphenylurea having the formula (I) or a salt thereof, where Y is CO=O, C=S, C=NH, (C=O)2 or SO2; and to processes for the preparation of these compounds and to their use in the treatment of protozoal disease...
|
|
WO/2003/005025A1 |
The present invention relates to a method for identifying compounds capable of binding the ligand binding domain of peroxisome proliferator-activated receptor gamma (PPAR$g(g)), and selectively modulating the activity of PPAR$g(g). The s...
|
|
WO/2003/002524A2 |
The present invention relates to compounds of the formula I, in which R?1¿, R?2¿, R?4¿, R?5¿, D¿1?, D¿2?, X¿1?, X¿2?, X¿3?, A and B have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacol...
|
|
WO/2003/002519A1 |
The invention relates to novel phenol derivatives, a method for the production of said derivatives and their use in medicaments.
|
|
WO/2003/000653A1 |
The invention relates to novel substituted N-acyl aniline derivatives of general formula (I), where R?1¿ to R?5¿, A, X, Y and Z are as defined in claim 1, the tautomers, stereoisomers, mixtures, prodrugs, derivatives with a group, nega...
|
|
WO/2002/100836A2 |
Methods and compositions useful in the treatment of amyloidosis and conditions and diseases associated therewith, such as Alzheimer's disease; are provided. The methods involve administering to a subject in need thereof a pharmaceutical ...
|
|
WO/2002/098849A2 |
Disclosed are compounds of formula X, where R¿n?, R¿20?, R¿1?, R¿2?, R¿3?, and R¿c? are defined herein. These compounds are useful in treating Alzheimer's disease and other similar diseases. Pharmaceutical compositions comprising c...
|
|
WO/2002/096864A1 |
The invention relates to carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments, physiologically-acceptable salts and physiologically-functional derivatives thereof. Compounds of formula (I), in w...
|
|
WO/2002/096884A2 |
The invention relates to novel substituted benzoylketones of formula (I), in which Q = O (oxygen) or S (sulphur), R?1¿ - R?5¿ and Z have the meaning given in the description and several methods for production thereof and use thereof as...
|
|
WO/2002/096863A1 |
The present invention relates to certain phenalkyloxy-phenyl derivatives of formula (I) and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for ...
|
|
WO/2002/096876A1 |
Disclosed are novel aromatic compounds of the formula (I) described herein, wherein G, E, W, Ar, X, Y and Z are disclosed herein. The compounds are useful for treating cytokine mediated diseases or conditions such as chronic inflammatory...
|
|
WO/2002/092574A1 |
The invention relates to novel substituted benzoylcyclohexenones of formula (I), in which Q, R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, Y and Z are defined as per the description. The invention also relates to a method for their production and t...
|
|
WO/2002/090336A1 |
The invention relates to novel arylketones of formula (I) wherein A?1¿, A?2¿, Q, R?1¿, R?2¿, X, Y and Z have the meaning cited in the description, the use thereof as herbicides and to methods and intermediate products for the product...
|
